Given that Stat3 activity promotes chemotherapy resistance [35,36], and the results that H182 in combination with cisplatin or docetaxel had a synergistic effect against breast cancer cells in vitro (Fig. 6B), we were interested to determine the antitumor efficacy of combining H182 and radiation therapy. This evidence concerns the gene STAT3 and breast cancer.